| INTRODUCTION
Head and neck cancers represent a major human health concern affecting over half a million individuals worldwide every year. 1 In the United States,~50 000 new cases are reported annually, a majority of whom present with locally advanced disease. 2 The standard of care for head and neck squamous cell carcinomas (HNSCC) involves a combination of surgery, chemotherapy, and radiation therapy (RT). 3 However, response rates of HNSCC patients to current treatment regimens are relatively modest. Furthermore, HNSCC patients suffer from poor quality of life due to long-term radiation toxicities. 4 While development of image-guided radiation delivery schemes has minimized collateral radiation damage to normal tissues in the head and neck region, tumor hypoxia is a major therapeutic hurdle that significantly diminishes radiotherapeutic efficacy. 5, 6 As a result, there has been increased interest in developing approaches that can alleviate tumor hypoxia to improve RT. 7 These studies have focused on vascular remodeling using antiangiogenic agents such as bevacizumab to "normalize" blood vessels, 8 hypoxia targeting bioreductive drugs 9 or methods such as hyperbaric oxygen therapy to increase oxygen delivery. 10 An alternative strategy to alleviate tumor hypoxia is to modulate the metabolism and decrease oxygen consumption of tumor cells. 11 In this regard, the Food and Drug Administration (FDA)-approved antidiabetic drug, metformin (Met), has been shown to target cellular respiration by inhibiting mitochondrial complex I in the electron transport chain and inhibit glycometabolism of HNSCC cells in vitro. 12 Metformin has been previously shown to exhibit chemopreventive activity alone and in combination with agents such as curcumin against HNSCC. 13, 14 The effect of Met on proliferation and tumor growth has also been recently studied in xenograft models of HNSCC. 15 These published studies have mostly utilized histo- The overall goal of this study was to utilize a non-invasive, multimodal imaging approach to examine the impact of Met in an orthotopic xenograft model of HNSCC. To date, the effect of Met on tumor oxygenation in HNSCC has not been reported. To address this gap in knowledge, we employed photoacoustic imaging (PAI), a noninvasive hybrid imaging method that enables visualization and quantification of tumor oxygen saturation (%sO 2 ) by exploiting differences in optical absorption characteristics of oxygenated and deoxygenated hemoglobin. 16, 17 Experimental studies were conducted in an orthotopic model of HNSCC to determine whether PAI could provide non-invasive assessment of improved tumor oxygenation following Met therapy. In addition to PAI, the in vivo effects of Met on tumor growth and metabolism were studied using magnetic resonance imaging (MRI) and fluorescence imaging (FI), respectively.
Immunohistochemical staining of tumors for markers of proliferation (Ki67) and vascularity (CD31) was used to validate the effects of Met within the tumor microenvironment.
| MATERIALS AND METHODS

| Animals
Eight to twelve-week-old female CB. 
| Fluorescence imaging
Intratumoral uptake of the fluorescent probe, 2-DeoxyGlucosone | 485 acquired on the axial plane for each mouse to measure tumor volume using the following parameters; matrix size: 256 9 192, TE/ TR = 41/2500 ms, slice thickness: 1 mm, field of view (FOV):
3.2 9 3.2 cm, number of slices = 20. An ROI was manually traced around the entire tumor on multiple slices to calculate tumor volume as described previously. 18 
| Immunohistochemistry
Tumors from control and Met-treated animals were excised and placed in fixative for immunostaining and histology. Tumor proliferation index was estimated using Ki-67-stained specimens (mAb;
Dako-M7240). Five random areas were captured at 409 magnification and analyzed using NIH Image J software (NIH, Maryland).
Staining intensity was categorized into 1 = negative/no stain, 2 = weak, 3 = moderate, and 4 = strong. For each image, 100 cells with nuclei were assessed for staining intensity and assigned a value from 1 to 4. The scores were assessed by an observer who was blinded to the identity of the samples. The H-scores for Ki-67 were calculated as the sum scores of all the 500 cells per sample.
Microvessel density was estimated by counting CD31 (MEC13; BD Pharmingen-550274) positive endothelial clusters with a visible lumen on stained tissue sections. Stained slides were scanned and digitized using Scanscope XT (Aperio Technologies, Vista, CA).
| Study design and statistical considerations
The experimental outline of the study to employ multimodal imaging (MRI, US, and FI) for examining the response of orthotopic HNSCC xenografts to metformin (Met) treatment is shown in Figure 1A .
Female SCID mice bearing orthotopic FaDu tumors (n = 10) were treated with Met at a dose of 200 mg/kg by intraperitoneal (ip) injection for five days. Control animals (n = 7) received water for the same duration. MRI was performed to measure tumor volume before and after treatment. PAI and FI were used to measure tumor hemodynamics and 2-DG uptake 24 hours after completion of treatment.
Tumors were excised from control (n = 5) and treated (n = 7) animals to perform immunohistochemical analysis following completion of imaging. All statistical analysis was performed using GraphPad Prism (GraphPad Software, San Diego, CA). Reported values represent mean AE standard error. Difference in imaging parameters between control and treated tumors was analyzed using unpaired t F I G U R E 1 A, Schematic shows the experimental outline for multimodal imaging-based assessment HNSCC response to metformin (Met) treatment. MRI was performed to measure tumor volume before and after treatment. PAI and FI were used to measure tumor hemodynamics and 2-DG uptake, respectively, at the end of treatment. However, this change was not statistically significant ( Figure 2D ).
| Effect of Met treatment on salivary gland hemodynamics
To measure the effect of Met on normal tissue hemodynamics, we assessed change in %sO 2 and HbT (Figure 3 ) of mouse salivary glands. Figure 3A 
| DISCUSSION
There has been considerable preclinical and clinical investigation into the chemopreventive and therapeutic potential of Met against HNSCC. [11] [12] [13] [14] [15] 21 As such, Met is undergoing clinical evaluation in "window of opportunity" trials in HNSCC patients. 22, 23 A recent clinical study has demonstrated that Met is also well tolerated in HNSCC patients. 23 In the present study, we examined the effects of Met treatment within the tumor microenvironment using multimodal imaging. Table 1 summarizes the key observations of our study. The dose and schedule of Met used in our study were selected based on preliminary dose-response studies conducted in our laboratory using subcutaneous FaDu xenografts ( Figure S1B ). This dose of Met was well tolerated without any evidence of toxicity based on body weight measurements.
We utilized non-invasive MRI to measure tumor volume changes following Met treatment as it offers superior soft tissue contrast without the use of ionizing radiation or radioactive isotopes. MRI enabled visualization and accurate quantification of tumor burden in the oral cavity of mice. As a single agent, we observed a modest but significant inhibition of tumor growth (MRI). Consistent with our MRI results and published observations in preclinical models, [13] [14] [15] immunostaining of tumor section for the proliferation marker, Ki67 showed a reduction in Met-treated tumors compared to controls.
Fluorescence imaging was used to examine the intratumoral uptake of optically labeled 2-DG probe following Met treatment.
Higher uptake of the fluorescent 2-DG probe has been reported in hypoxic regions of Cal33 HNSCC xenografts, presumably due to the Warburg effect. 20 In our study, Met-treated tumors showed lower 2-DG uptake compared to control tumors. However, the difference between the two groups was not significant. Unlike MRI or PAI measurements, in the present study, fluorescence imaging measurements were performed in 2D and can therefore be influenced by the depth of tumors. In addition, Tseng et al 24 have shown that uptake of NIR 2-DG probes is influenced by the enhanced permeability and In this regard, our results highlight the potential of PAI as a powerful, non-invasive tool for real-time assessment of early changes in tumor oxygenation following Met therapy that could potentially enable identification of an optimal window for administering RT in combination with Met.
